Anteris Technologies Global Corp.

Anteris Technologies is a cardiac medical device company focused on transcatheter aortic valve replacement (TAVR) solutions. The company develops and commercializes the DurAVR® Transcatheter Heart Valve (THV), a single-piece, native-shaped biomimetic device designed to mimic the performance of a healthy aortic valve. DurAVR® is engineered to address clinical gaps in aortic valve disease treatment, particularly for patients with small aortic annuli, where it demonstrates superior hemodynamic performance compared to competing TAVR platforms. Key clinical advantages include favorable effective orifice area (EOA), low mean pressure gradients, and notably high freedom from prosthesis-patient mismatch (PPM)—a recognized predictor of valve failure and long-term patient mortality. The company conducts clinical trials including the PARADIGM trial, the first all-comers, head-to-head TAVI comparison designed to evaluate post-procedure blood flow patterns using cardiac MRI. Anteris has FDA IDE approval and is enrolled across 80 centers in the US, Canada, and Europe. The company is publicly traded, with operations in Australia (Brisbane headquarters for annual meetings) and the US, as evidenced by SEC and ASX filings. Manufacturing and clinical development capabilities support valve design, bench testing, hemodynamic analysis, and multi-center clinical evaluation.